Nasonex and Entyvio drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Nasonex (mometasone furoate monohydrate) and Entyvio (vedolizumab). Common drug interactions include blood magnesium increased among females and abdominal pain among males.

The phase IV clinical study analyzes what interactions people have when they take Nasonex and Entyvio. It is created by eHealthMe based on reports of 24 people who take the same drugs from the FDA, and is updated regularly.

What is Nasonex?

Nasonex has active ingredients of mometasone furoate monohydrate. It is often used in allergies. eHealthMe is studying from 32,299 Nasonex users. Check the latest studies of Nasonex.

What is Entyvio?

Entyvio has active ingredients of vedolizumab. It is often used in crohn's disease. eHealthMe is studying from 23,827 Entyvio users. Check the latest studies of Entyvio.

On Jul, 26, 2026

24 people who take Nasonex and Entyvio together, and have interactions are studied.

What are the common drug interactions of Nasonex and Entyvio, by gender? *:

female:

Blood magnesium increased
Dehydration (dryness resulting from the removal of water)
Drug ineffective
Frequent bowel movements
Inflammatory bowel disease
Injection site erythema (redness at injection site)
Maternal exposure during pregnancy (use of substance during pregnancy)
Psoriatic arthropathy (inflammation of the skin and joints with kin condition which typically causes patches (plaques) of red, scaly skin to develop)
Seizure (abnormal excessive or synchronous neuronal activity in the brain)
Sepsis (a severe blood infection that can lead to organ failure and death)

male:

Abdominal pain
Diarrhoea
Gastrointestinal bacterial infection (infection of the stomach and intestines caused by bacteria)
Ulcer
Visual impairment
Blood glucose increased
Infection parasitic
Drug ineffective
Haematochezia (passage of stools containing blood)
Hypertension (high blood pressure)

What are the common drug interactions of Nasonex and Entyvio, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

Alopecia (absence of hair from areas of the body)
Arthralgia (joint pain)
Arthritis (form of joint disorder that involves inflammation of one or more joints)
Gait disturbance
Mobility decreased (ability to move is reduced)
Pain in extremity
Pancreatitis (inflammation of pancreas)
Peripheral swelling
Soft tissue disorder (disease of soft tissue)

40-49:

n/a

50-59:

n/a

60+:

Abdominal pain
Diarrhoea
Gastrointestinal bacterial infection (infection of the stomach and intestines caused by bacteria)
Ulcer
Visual impairment
Blood glucose increased
Infection parasitic
Drug ineffective
Haematochezia (passage of stools containing blood)
Blood glucose decreased

What are the existing conditions these people have? *

Ulcerative Colitis (inflammatory bowel disease (ibd). it causes swelling, ulcerations, and loss of function of the large intestine): 7 people, 29.17%
Diabetes: 3 people, 12.50%
Short-Bowel Syndrome (a condition in which the body cannot absorb enough fluids and nutrients because part of the small intestine is missing): 2 people, 8.33%
Psoriatic Arthropathy (inflammation of the skin and joints with kin condition which typically causes patches (plaques) of red, scaly skin to develop): 2 people, 8.33%
Malabsorption (a state arising from abnormality in absorption of food nutrients across the gastrointestinal (gi) tract): 2 people, 8.33%
Hypergammaglobulinaemia (elevated levels of gamma globulin): 2 people, 8.33%
Hiv Infection: 2 people, 8.33%
Chronic Inflammatory Demyelinating Polyradiculoneuropathy (long lasting infection of nerves outside brain and spinal cord): 2 people, 8.33%
Amino Acid Metabolism Disorder: 2 people, 8.33%

* Approximation only. Some reports may have incomplete information.

Do you take Nasonex and Entyvio?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously